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A B S T R A C T
Five new platinum(IV) derivatives of carboplatin each incorporating the histone deacetylase inhibitor 4-phe-
nylbutyrate in axial position were synthesized and characterized by 1H and 195Pt NMR spectroscopy, electro-
spray ionization mass spectrometry and elemental analysis, namely cis,trans-[Pt(CBDCA)(NH3)2(PBA)(OH)] (1),
cis,trans-[Pt(CBDCA)(NH3)2(PBA)2] (2), cis,trans-[Pt(CBDCA)(NH3)2(PBA)(bz)] (3), cis,trans-[Pt(CBDCA)
(NH3)2(PBA)(suc)] (4) and cis,trans-[Pt(CBDCA)(NH3)2)(PBA)(ac)] (5) (PBA = 4-phenylbutyrate, CBDCA = 1,1-
cyclobutane dicarboxylate, bz = benzoate, suc = succinate and ac = acetate). The reduction behavior in the
presence of ascorbic acid was studied by high performance liquid chromatography. The cytotoxicity against a
panel of human tumor cell lines, histone deacetylase (HDAC) inhibitory activity, cellular accumulation and the
ability to induce apoptosis were evaluated. The most effective complex, compound 3, was found to be up to ten
times more effective than carboplatin and to decrease cellular basal HDAC activity by approximately 18% in
A431 human cervical cancer cells.
1. Introduction
Platinum(IV) prodrugs are Pt(IV) complexes that on intracellular
reduction release the axial ligands and the active square-planar pla-
tinum(II) species. Thus, conjugating a biologically active ligand to one
or both axial positions of a platinum(IV) derivative of an anticancer
platinum(II) drug is widely studied as a strategy for dual-action agents
that target two distinct and/or independent cellular mechanisms [1].
Prominent examples are the Pt(IV) analogs of cisplatin ethacraplatin
[2,3], chalcoplatin [4], aplatin [5,6] and mitaplatin [7] with the glu-
tathione-S-transferase inhibitor ethacrynic acid, a chalcone derivative
acting as a p53 inhibitor, the COX inhibitor acetylsalicylate and the
apoptosis sensitizer dichloroacetate in axial position, respectively
(Fig. 1). Furthermore, phosphatase 2A inhibitors [8], the vitamin E
analog α-tocopheryl succinate [9], carbohydrates [10,11], nucleotide
excision repair inhibitors [12], alkylating agents [13] as well as redox
modulators [14] have been attached to the cisplatin and oxaliplatin
scaffold.
Carboplatin (cis-diammine-1,1-cyclobutanedicarboxylatoplatinum
(II)), a second generation platinum(II) drug used in the treatment of
ovarian cancer, retinoblastomas, neuroblastomas, nephroblastomas,
brain, head and neck, cervical, testicular, breast, lung and bladder
cancers, shows a more favorable toxicity profile compared to cisplatin
and is generally better tolerated [15]. The chelating dicarboxylate
leaving group is hydrolyzed more slowly than the monodentate
chlorido ligands in cisplatin, thus reducing off-target binding to bio-
molecules prior to DNA coordination. Platinum(IV) complexes based on
carboplatin have been synthesized with various biologically inactive
axial ligands and their pharmacokinetic properties and structure-ac-
tivity relationship have been studied [16–20]. A Pt(IV) prodrug of
carboplatin has also been modified with a polymeric nanodelivery
carrier [21]. However, to the best of our knowledge, in contrast to dual-
action prodrugs of cis- and oxaliplatin, platinum(IV) complexes with
bioactive ligands attached to the carboplatin platform seem to have
remained unexplored so far.
Histone deacetylase inhibitors (HDACi) are known to enhance the
effect of DNA damaging agents [22]. Belinostat, for example, reverses
platinum resistance in platinum-resistant lung cancer cells when co-
administered with cisplatin [23] and Trichostatin A has an additive
effect with oxaliplatin in gastric tumor cells [24]. Histone deacetylase
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(HDAC) regulates chromatin structure and transcription [25]. Its in-
hibition induces hyperacetylation of histone proteins around which
DNA coils, making DNA more accessible within chromatin [26]. HDACi
have also been shown to interact with non-histone proteins, including
proteins that play a key role in cellular proliferation, migration, cell
death, DNA repair, immune response, angiogenesis and inflammation
[27]. Several HDACi are effective anticancer agents and have entered
clinical trials [28]. They generally have few adverse effects on healthy
cells.
Marmion and coworkers developed platinum(II) complexes with
HDAC inhibitory ligands. They reported enhanced selectivity for cis-
platin complexes of functionalized suberoylanilide hydroxamic acid
[29,30] and belinostat [31] and enhanced cytotoxicity of transplatin
complexes of valproate compared to cisplatin [32]. Brabec and cow-
orkers studied platinum(IV) prodrugs of oxaliplatin with axial valproate
ligands [33]. While displaying lower cytotoxicity than oxaliplatin in
cell culture, the complexes showed enhanced accumulation in tumor
cells and were active in cisplatin-resistant cells. The platinum(IV)
complex cis,cis,trans-[Pt(NH3)2Cl2(valproate)2] was shown to exert
significant cytotoxicity in a range of human carcinoma cell lines, in-
cluding malignant pleural mesothelioma cells [34–36]. A larger fraction
of total platinum taken up by cells was found to bind to DNA, when
platinum(IV) complexes containing biologically active axial ligands
were used compared to platinum(IV) complexes with biologically in-
active axial ligands [34]. Kasparkova et al. recently reported a photo-
activatable platinum(IV) complex with axial suberoylanilide hydro-
xamic acid ligands [37]. Gibson and coworkers attached the HDACi 4-
phenylbutyric acid (PBA) and valproate to the axial positions of Pt(IV)
derivatives of cisplatin and oxaliplatin [38,39]. Cis,trans,cis-[Pt
(NH3)2(PBA)2Cl2] was found to be up to 100-fold more potent than
cisplatin [38]. Inhibition of HDAC activity by 60–70% in cancer cells at
concentrations lower than the IC50 value of PBA suggested a synergism
between platinum and PBA.
The apparent lack of studies on the functionalization of platinum
(IV) derivatives of carboplatin with bioactive ligands prompted us to
prepare platinum(IV) complexes with HDAC inhibitory ligands based
on the carboplatin scaffold. Here we report the synthesis, character-
ization, cytotoxicity and HDAC inhibitory activity of a series of pla-
tinum(IV) prodrugs of carboplatin with PBA as an axial ligand.
2. Experimental
2.1. Materials and methods
Reactions were performed under normal atmospheric conditions
using as-received analytical or HPLC grade solvents and reagents from
commercial suppliers. K2PtCl4 was purchased from Acros Organics, 4-
phenylbutyric acid, acetic anhydride and succinic anhydride were ob-
tained from Sigma-Aldrich and benzoic acid, N-hydroxysuccinimide
and dicyclohexylcarbodiimide from TCI Europe. The ultra-pure water
used was purified with a Milli-Q UV purification system. Carboplatin
and oxo-carboplatin (trans,cis-[Pt(CBDCA)(OH)2(NH3)2]) were synthe-
sized according to the previously reported procedures [40].
2.2. Syntheses
2.2.1. NHS ester of 4-phenylbutyric acid
4-Phenylbutyric acid (2.0 g, 12.2 mmol) and N-hydroxysuccinimide
(1.4 g, 12.2 mmol) were dissolved in tetrahydrofuran (20 mL), followed
by dropwise addition of a solution of dicyclohexylcarbodiimide (2.5 g,
12.2 mmol) in tetrahydrofuran (12 mL). The mixture was stirred at
room temperature for 7 h and then filtered to remove the dicyclohex-
ylurea precipitate. The filtrate was concentrated under reduced pres-
sure. The residue was dissolved in ethyl acetate (60 mL) and left at 4 °C
overnight. After filtration to remove the insoluble residue the organic
phase was washed with NaHCO3 solution (6%, 120 mL) and water
(60 mL) and dried over Na2SO4. Petroleum ether (60 mL) was then
added to the ethyl acetate solution to precipitate the 4-PBA-NHS ester
which was filtered off, washed with petroleum ether, dried, and pur-
ified by column chromatography (silica gel; 9:1 petroleum ether:ethyl
acetate). Yield: 3.1 g (96%); 1H NMR (500 MHz, CDCl3): δ 1.93–2.01
(m, 2H, CH2CH2CH2), 2.58 (t, J= 7.5 Hz, 2H, CH2CH2CH2), 2.73 (t,
J= 7.4 Hz, 2H, CH2CH2CH2), 2.80 (s, 4H, COCH2CH2CO), 7.20–7.29
(m, 5H, Har); ESI-MS: m/z= 261 [M-H]−.
2.2.2. cis,trans-[Pt(CBDCA)(NH3)2(PBA)(OH)] (1)
The 4-PBA-NHS ester (87.2 mg, 0.34 mmol) was added to cis,trans-
[Pt(CBDCA)(NH3)2(OH)2] (150 mg, 0.37 mmol) in dimethyl sulfoxide
(17 mL) and the mixture was stirred for 48 h at 65 °C. Unreacted cis,-
trans-[Pt(CBDCA)(NH3)2(OH)2] was removed by filtration, the solvent
was evaporated using a freeze-dryer and the residue was dissolved in
dimethylformamide (4 mL), followed by precipitation of the desired
product with diethyl ether. The precipitate was isolated by cen-
trifugation, washed several times with dichloromethane (2 mL) and
diethyl ether (20 mL) and dried under vacuum. Yield: 144 mg (71%).
Anal. Calcd (%) for C16H24N2O7Pt (551.45): C, 34.84; H, 4.35; N, 5.08.
Found: C, 34.63; H, 4.28; N, 5.09. 1H NMR (DMSO‑d6, 500 MHz): δ
1.6–1.7 (m, 4H, CCH2CH2, CBDCA and CH2CH2CH2, PBA), 2.13 (t,
J= 7.4 Hz, 2H, CH2CH2CH2), 2.42 (t, J= 8.1 Hz, 2H, CCH2CH2,
CBDCA), 2.56 (m, 4H, CCH2CH2, CBDCA, CH2CH2CH2, PBA), 5.97 (m,
br., 6H, NH3), 7.13–7.25 (m, 5H, Har); 195Pt{1H} NMR (107.6 MHz,
DMF/D2O): δ 1741 (quin, JPtN = 322 Hz). ESI-MS: m/z= 550.45.0 [M-
H]−.
2.2.3. cis,trans-[Pt(CBDCA)(NH3)2(PBA)]·0.5H2O (2)
The 4-PBA-NHS ester (1.546 g, 5.9 mmol) was added to cis,trans-[Pt
(CBDCA)(NH3)2(OH)2] (120 mg, 0.29 mmol) in dimethyl sulfoxide
(20 mL). After stirring for 72 h at 80 °C the mixture was concentrated to
a 2 mL volume and the desired product was precipitated by addition of
water (20 mL). The solid was isolated by centrifugation, washed several
times with dichloromethane (4 mL) and diethyl ether (40 mL) to re-
move excess ligand and dried under vacuum. Yield: 130 mg (64%).
Anal. Calcd (%) for C26H35N2O8.5Pt (706.66): C, 44.19; H, 4.99; N,
3.96. Found: C, 44.18; H, 4.85; N, 4.01. 1H NMR (DMSO‑d6, 500 MHz):
δ 1.6–1.7 (m, 2H, CH2CH2CH2, PBA), 1.8 (m, 2H, CCH2CH2, CBDCA),
2.18 (t, J= 7.4 Hz, 2H, CH2CH2CH2), 2.43 (t, J= 8.1 Hz, 2H,
CCH2CH2, CBDCA), 2.50 (t, J= 7.4 Hz, 2H, CH2CH2CH2), 2.64 (t,
J= 8.0 Hz, 2H, CCH2CH2, CBDCA), 6.34 (m, br., 6H, NH3), 7.19–7.29
(m, 10H, Har); 195Pt{1H} NMR (107.6 MHz, DMF/D2O): δ 1929 (quin,
JPtN = 215 Hz). ESI-MS: m/z= 696.15 [M-H]−.
Fig. 1. Examples for dual-action anticancer Pt(IV) complexes reported in the literature.
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2.2.4. cis,trans-[Pt(CBDCA)(NH3)2(PBA)(bz)] (3) and cis,trans-[Pt
(CBDCA)(NH3)2(PBA)(suc)] (4)
The unsymmetrically substituted complexes 3 and 4 were synthe-
sized by reaction of 1 with the respective carboxylic acid anhydride.
Complex 1 and 10 equivalents benzoic or succinic acid anhydride were
suspended in dimethylformamide and the mixture was stirred for 2 d at
80 °C. The solution was concentrated under reduced pressure and die-
thyl ether (40 mL) was added to precipitate the desired product which
was isolated by centrifugation and washed with dichloromethane
(4 mL) and diethyl ether (4 mL) to remove residual dimethylforma-
mide.
Complex 3: Yield: 100 mg (61%) from 1 (140 mg, 0.25 mmol) and
benzoic anhydride (574 mg, 2.5 mmol) in 20 mL dimethylformamide.
Anal. Calcd (%) for: C23H28N2O8Pt (655.56): C, 42.14; H, 4.31; N, 4.27.
Found: C, 42.01; H, 4.11; N, 4.09. 1H NMR (DMSO‑d6, 500 MHz): δ
1.7–1.8 (m, 4H, CCH2CH2, CBDCA and CH2CH2CH2, PBA), 2.22 (t,
J= 7.4 Hz, 2H, CH2CH2CH2), 2.45 (m, 2H, CH2CH2CH2), 2.53 (t,
J= 8.0 Hz, 4H, CCH2CH2, CBDCA), 6.4 (m, br., 6H, NH3), 7.10–7.23
(m, 5H, Har, PBA), 7.37 (t, J= 8.0, 2H, Har), 7.46 (t, J= 8.0, 1H, Har),
7.85 (d, J= 6.9 Hz, 2H, Har); 195Pt{1H} NMR (107.6 MHz, DMF/D2O):
δ 1931 (quin, JPtN = 206 Hz). ESI-MS: m/z= 654.14 [M-H]−.
Complex 4: Yield: 90 mg (77%) from 1 (100 mg, 0.18 mmol) and
succinic anhydride (181 mg, 0.81 mmol) in 20 mL dimethylformamide.
Anal. Calcd (%) for: C20H28N2O10Pt (651.53): C, 36.87; H, 4.33; N,
4.30. Found: C, 36.74; H, 4.23; N, 4.20. 1H NMR (DMSO‑d6, 500 MHz):
δ 1.7–1.8 (m, 4H, CCH2CH2, CBDCA and CH2CH2CH2, PBA), 2.20 (t,
J= 7.4 Hz, 2H, CH2CH2CH2), 2.32–2.59 (m, 10H, CH2CH2CH2,
CCH2CH2, CBDCA, CH2, suc), 6.3 (m, br., 6H, NH3), 7.13–7.24 (m, 5H,
Har); 195Pt{1H} NMR (107.6 MHz, DMF/D2O): δ 1934 (quin,
JPtN = 210 Hz). ESI-MS: m/z= 650.52 [M-H]−.
2.2.5. cis,trans-[Pt(CBDCA)(NH3)2)(PBA)(ac)] (5)
Complex 1 (56 mg, 0.10 mmol) was stirred for 20 h in acetic an-
hydride (5 mL) at room temperature. The mixture was then lyophilized
and washed with diethyl ether (2 × 5 mL) to isolate the desired pro-
duct. Yield: 35 mg (60%). Anal. Calcd (%) for C18H26N2O8Pt (593.13):
C, 36.43; H, 4.42; N, 4.72. Found: C, 36.34; H, 4.36; N, 4.60. 1H NMR
(DMSO‑d6, 500 MHz): δ 1.7–1.8 (m, 4H, CCH2CH2, CBDCA and
CH2CH2CH2, PBA), 1.96 (s, 3H, CH3COO), 2.20 (t, J= 7.4 Hz, 2H,
CH2CH2CH2), 2.4–2.6 (m, 6H, CH2CH2CH2, PBA, CCH2CH2, CBDCA),
6.3 (m, br., 6H, NH3), 7.11–7.24 (m, 5H, Har); 195Pt{1H} NMR
(107.6 MHz, DMF/D2O): δ 1935 (quin, JPtN = 208 Hz). m/z= 592.17
[M-H]−.
2.3. Measurements and instrumentation
1H, 13C and 195Pt NMR spectra were acquired with a Varian 500 AR
spectrometer. Chemical shifts are given in parts per million (ppm) with
tetramethylsilane as the reference (δ (1H NMR) = 0 ppm). Coupling
constants (J) are given in Hertz (Hz). 195Pt NMR spectra were acquired
in dimethylformamide with an inserted tube containing D2O. K2PtCl6 in
D2O was used as an external reference. Mass spectra were obtained with
a Waters LCT Premiere XE with electron spray ionization and time of
flight mass analyzer. Elemental analyses (carbon, nitrogen and hy-
drogen) were carried out with a PerkinElmer 2400 series II analyzer.
Platinum concentrations were determined using inductively coupled
plasma mass spectrometry (ICP-MS, ELAN DRCe, PerkinElmer,
Waltham, USA) in a Class 1000 cleanroom [41–44]. Instrumental op-
erating conditions included: ICP RF Power 1150 W: plasma gas flow
15 L min−1; auxiliary gas flow 1 L min−1; nebuliser gas flow
0.93 L min−1; observed isotopes; 192Pt, 194Pt, 195Pt, 196Pt and 198Pt.
Platinum calibration standards were prepared using a single element Pt
standard (SPEX CertiPrep, 1000 μg/mL) and Milli-Q™ water (18.3 mΩ)
(Millipore, Bedford, USA) with 1% HNO3 (Trace Metal Grade, 67–69%,
Fisher, UK). Iridium (191Ir) and indium (115In) were used as internal
standards to account for instrumental drift and matrix effects.
2.4. Reduction of the Pt(IV) complexes
The reduction of complexes 1, 2 and 3 was monitored by high
performance liquid chromatography (HPLC) using an Agilent 1200
series DAD analytical HPLC instrument. The compounds were dissolved
in 0.5 mL dimethylformamide, added to a 7 mM solution of ascorbic
acid in 4 mM 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid
(HEPES) buffer (pH 7) and diluted with acetonitrile to a final con-
centration of 0.5 mM. The reduction was monitored at 37 °C until
completion. The samples were analyzed using a Phenomenex Luna C18
column (5 μm, 100 Å, 250 mm× 4.60 mm i.d.). The mobile phase was
90:10 acetonitrile (1% trifluoroacetic acid):water (1% trifluoroacetic
acid). The flow rate was 1.0 mL min−1 and the fractions were detected
at 254 nm.
2.5. Determination of lipophilicity
Octanol-water partition coefficients (log Po/w) of the Pt(IV) com-
pounds were determined by the shake flask method [45]. All experi-
ments were done in duplicate. The respective Pt(IV) complex was mixed
with 0.9% NaCl (w/v) in ultrapure water that was presaturated with n-
octanol for 3 d. All solutions were sonicated and filtered to remove
undissolved Pt(IV) compound. The initial Pt concentrations were
measured by ICP-MS (ELAN DRCe, Perkin Elmer, Waltham, USA) as
described above. Subsequently, the Pt(IV) solution was added to an
equal volume of n-octanol that was presaturated with 0.9% NaCl (w/v)
in ultrapure water. The heterogeneous mixture was shaken vigorously
for 1 h before centrifuging at 4400 rpm for 1 h to achieve phase se-
paration. The final Pt concentration in the aqueous phase was measured
again by ICP-MS. Log Po/w values were calculated as the ratio of Pt
concentrations in the organic and aqueous phases.
2.6. Experiments with cultured human cells
The Pt(IV) complexes and the corresponding uncoordinated ligands
were dissolved in dimethyl sulfoxide just before the experiment and a
calculated amount of drug solution was added to the cell growth
medium to a final solvent concentration of 0.5%, which had no de-
tectable effect on cell killing. Cisplatin and carboplatin were dissolved
in 0.9% sodium chloride solution. MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide), carboplatin and cisplatin were ob-
tained from Sigma Chemical Co, St. Louis, USA.
2.7. Cell cultures
The human pancreatic (BxPC3) and colon (LoVo) carcinoma and
melanoma (A375) cell lines were obtained from American Type Culture
Collection (ATCC, Rockville, MD). The human squamous cervical
cancer cell line (A431) was kindly provided by Prof. G. Zunino
(Division of Experimental Oncology B, Istituto Nazionale dei Tumori,
Milan, Italy).
Cell lines were maintained in the logarithmic phase at 37 °C in a 5%
carbon dioxide atmosphere using the following culture media con-
taining 10% fetal calf serum (Euroclone, Milan, Italy), antibiotics
(50 units/mL penicillin and 50 μg/mL streptomycin), and 2 mM L-glu-
tamine: (i) RPMI-1640 medium (Euroclone) for BxPC3 and A431 cells;
(ii) DMEM for A375 cells; (iii) F-12 HAM'S (Sigma Chemical Co.) for
LoVo cells.
2.8. MTT assay
The growth inhibitory effect toward tumor cells was evaluated by
means of MTT assay. Briefly, (3–8) × 103 cells/well, dependent upon
the growth characteristics of the cell line, were seeded in 96-well mi-
croplates in growth medium (100 μL). After 24 h, the medium was re-
moved and replaced with fresh medium containing the compound to be
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studied at the appropriate concentration. Triplicate cultures were es-
tablished for each treatment. After 72 h, each well was treated with
10 μL of a 5 mg/mL MTT saline solution and following 5 h of incuba-
tion, 100 μL of a sodium dodecylsulfate (SDS) solution in HCl (0.01 M)
was added. After an overnight incubation, cell growth inhibition was
detected by measuring the absorbance of each well at 570 nm using a
Bio-Rad 680 microplate reader. The mean absorbance for each drug
dose was expressed as a percentage of the untreated control well ab-
sorbance and plotted vs. drug concentration. IC50 values, the drug
concentrations that reduce the mean absorbance at 570 nm to 50% of
those in the untreated control wells, were calculated by a four para-
meter logistic (4-PL) model. All of the values are the means ± SD of
not less than five independent experiments.
2.9. Cellular accumulation
A431 cells (2 × 106) were seeded in 75 cm2 flasks in growth
medium (20 mL). After overnight incubation, the medium was replaced
and the cells were treated with the tested compounds for 24 h. Cell
monolayers were washed twice with cold PBS, harvested and counted.
Samples were subjected to three freezing/thawing cycles at−80 °C and
then vigorously vortexed. The samples were treated with highly pure
nitric acid (Pt: ≤0.01 μg kg−1, TraceSELECT® Ultra, Sigma Chemical
Co.) and transferred into a microwave teflon vessel. Subsequently,
samples were submitted to standard procedures using a speed wave
MWS-3 Berghof instrument (Eningen, Germany). After cooling, each
mineralized sample was analyzed for platinum by using a Varian AA
Duo graphite furnace atomic absorption spectrometer (Varian, Palo
Alto, CA; USA) at the wavelength of 324 nm. The calibration curve was
obtained using known concentrations of standard solutions purchased
from Sigma Chemical Co.
2.10. Histone deacetylase assay
Histone deacetylase activity was determined using Fluor-de-
Lys®HDAC fluorometric activity assay kit (Enzo Life Sciences
International, Inc., Plymount Meeting, PA, U.S.A.). A431 cells (5 × 104
seeded in 96-well microplates) were treated for 24 h with 5 μM tested
complexes, then processed as reported by the manufacturer's instruc-
tions. Fluorescence was measured using a Fluoroskan Ascent FL
(Labsystem, Finland) plate reader, with excitation at 360 nm and
emission at 460 nm.
2.11. Hoechst 33258 staining
A431 cells were seeded into 8-well tissue-culture slides (BD Falcon,
Bedford, MA, USA) at 5 × 104 cells/well (0.8 cm2). After 24 h, the cells
were washed twice with PBS and following 48 h of treatment with IC50
concentration of tested complexes, the cells were stained for 5 min with
1 mg/mL Hoechst 33258 (Sigma–Aldrich) in PBS before being ex-
amined by fluorescence microscopy (Olympus BX41, Cell F software,
Olympus, Munster, Germany).
3. Results and discussion
3.1. Synthesis and characterization
The chemical structures of the Pt(IV) complexes investigated in this
paper are depicted in Scheme 1. The dihydroxoplatinum(IV) derivative
of carboplatin (A) was obtained by oxidation of carboplatin with H2O2
in aqueous solution. The mono-substituted complex 1 could be syn-
thesized by reaction of the activated NHS-ester of PBA (see experi-
mental) and A (0.9:1 ratio) in dimethyl sulfoxide at 65 °C with a yield of
71%. The bis-substituted complex 2 was isolated after reaction of A
with a large excess of the activated NHS-ester of PBA. All the other
complexes were synthesized by reaction of the mono-PBA complex 1
with the corresponding anhydride (benzoic anhydride, 3; succinic an-
hydride, 4 and acetic anhydride, 5) in dimethylformamide with yields
in the range of 49–75% (Scheme 1). Each complex was characterized by
ESI-mass spectrometry, 1H and 195Pt NMR spectroscopy and the purity
was assessed by elemental analysis and HPLC. The 1H NMR spectra in
DMSO‑d6 displayed the typical signal of the NH3 protons of the car-
boplatin scaffold as a broad multiplet around 6 ppm in the case of
mono-substituted 1 and as a broad signal around 6.5 ppm in the case of
the bis-substituted complexes 2–5 (Supplementary Figs. S1 – S5). The
195Pt NMR spectra of the bis-substituted complexes (Supplementary
Figs. S6 – S10) showed a quintet around 1900 ppm while 1 gave a
quintet at 1741 ppm in line with chemical shift data previously re-
ported for related Pt(IV) complexes [14]. The appearance of the signals
as quintets is due to spin-to-spin coupling between 195Pt and two 14N
nuclei. The mass spectra of the complexes displayed a peak in the ne-
gative mode with the typical platinum isotope pattern corresponding to
the respective [M− H]− species (Supplementary Figs. S11 – S15).
The different axial carboxylate ligands tune the lipophilicity of the
complexes; the log Po/w values, determined for each complex using the
shake flask method, are reported in Scheme 1 and indicate the order of
lipophilicity as 2 > 3 > 5 > 1 > 4 as expected. Pt(IV) complexes
enter the cell by passive diffusion and the lipophilicity index plays a
major role in cellular Pt accumulation [34]. The mechanism of action of
Pt(IV) complexes has been investigated in detail. The most important
step is the reduction of the complexes inside the cell environment to
produce the active Pt(II) species (carboplatin in this case) with the re-
lease of the axial ligands [46] and the pharmacological profiles of Pt
(IV) complexes are greatly affected by their redox behavior. High re-
duction rates might lead to high systemic toxicity and to deactivation of
the resulting Pt(II) form before the DNA is reached, whereas particu-
larly low reduction rates might result in the absence of antitumor ac-
tivity. While no direct correlation between the reduction potential and
prodrug efficacy has been established in the literature, a reduction
potential in the mid-range as observed for complexes with two axial
carboxylate ligands (~−600 mV) seems to be a good guideline for an
effective Pt(IV) prodrug [1]. The reduction of Pt(IV) complexes has
been investigated in the past with different techniques and under dif-
ferent conditions [47–51]. It is generally presumed that under physio-
logical conditions Pt(IV) is reduced by low-molecular-weight reducing
agents such as ascorbic acid or glutathione, although recently evidence
has been obtained that higher molecular weight biomolecules such as
metallothioneines can also play a major role in the reduction and ac-
tivation of Pt(IV) prodrugs [52]. Until recently the reduction rate – and
thus the biological activity – was assumed to directly correlate
with the Pt(IV)/Pt(II) redox potential. The latter is mainly determined
by the nature of the axial ligands. The redox potentials of Pt(IV) com-
plexes of general formula cis,trans,cis-[PtCl2L2(Am)2] decrease in the
order L = OH– (~−900 mV) < RCOO− (~−600 mV) < Cl−
(~−250 mV) [53]. Some exceptions have recently been reported
where the reduction rate does not correlate with the redox potential of
the Pt(IV) complex. In particular, it was found that mono-substituted
species with one axial OH group are reduced faster than bis-carboxy-
lated complexes due to the ability of the OH group to act as a bridging
ligands in an inner-sphere electron transfer mechanism [54,55]. In
summary, it is quite hard to predict and estimate the reduction rate of a
Pt(IV) complex, as many factors may come into play (e.g. Pt(II) scaffold,
nature of the axial ligands, reducing agent) [56,57]. The reduction with
ascorbic acid and the release of the PBA ligands under physiological
conditions (37 °C, pH 7) of the monocarboxylated complex 1, the bis-
PBA complex 2 and 3 as a representative of the mixed carboxylic acid
complexes, was monitored by HPLC (Fig. 2 and Supplementary Figs.
S16 and S17). Comparison of the HPLC chromatograms obtained during
the reduction reaction with that of the pure PBA ligand confirmed that
the reduction of Pt(IV) to Pt(II) leads to the release of the axial ligands.
Incubation with 10 eq. of ascorbic acid for 5 h resulted in the reduction
of 75% of complex 2 and 50% of complex 3. The complexes were
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reduced completely after 12 h (2), 36 h (3) and 72 h (1). Noteworthy,
for the reduction of complex 3 both released axial ligands (PBA and
benzoic acid) could be identified in the chromatogram.
3.2. Cytotoxicity
The ability of the Pt(IV) complexes 1–5 to promote cell death was
evaluated in several human cancer cell lines derived from solid tumors
(A431 cervical, LoVo colon, BxPC3 pancreatic and A375 melanoma
cells). The cytotoxicity parameters, in terms of IC50 values obtained
after 72 h of exposure to the MTT assay, are listed in Table 1. For
comparison purposes, the cytotoxicities of cisplatin and carboplatin
were assessed under the same experimental conditions. Cancer cell lines
included in the screen were endowed with different degrees of sensi-
tivity to cisplatin and carboplatin and showed a good concentration-
dependent response to treatment with the newly synthesized com-
plexes. The uncoordinated HDACi ligand PBA displayed very low cy-
totoxic activities, with IC50 values mainly in the millimolar range, in
agreement with the literature [38].
Complexes 1–4 were found to be more effective than the reference
metallodrug carboplatin, but only derivative 3 possessed an in vitro
antitumor activity comparable to that of cisplatin, with the average IC50
values being 6.8 and 6.0 μM for 3 and cisplatin, respectively. Actually,
3 emerged as the most cytotoxic derivative, eliciting mean IC50 values
from 3- to 5-fold lower than those calculated for the other complexes of
the series. It is noteworthy that complex 3 was roughly 1.8-fold more
effective than cisplatin against human BxPC3 pancreatic and LoVo
colon cancer cells and on average 5 and 10 times more effective than
carboplatin.
Scheme 1. Synthesis of the Pt(IV) com-
plexes 1–5.
Fig. 2. HPLC chromatogram of the reaction of 1 with 10 eq. ascorbic acid at 37 °C and
pH 7. The chromatogram of the free ligand PBA is shown for comparison purposes.
Table 1
IC50 values of 1–5 in different cancer cell linesa.
IC50 (μM) ± S.D.
A375 BxPC3 LoVo A431
1 18.5 ± 5.9 36.2 ± 8.3 13.5 ± 3.9 16.8 ± 3.6
2 16.6 ± 3.5 24.2 ± 3.2 13.5 ± 2.5 15.9 ± 3.7
3 11.1 ± 2.9 6.2 ± 0.3 5.1 ± 1.3 5 ± 2
4 24.2 ± 3.5 36.3 ± 3.2 18.4 ± 2.9 19.7 ± 5.1
5 23.3 ± 6.2 34.6 ± 3.1 39.3 ± 4.2 25.3 ± 2.3
Carboplatin 13.5 ± 3.0 30.9 ± 4.2 49.3 ± 7.1 12.3 ± 3.3
PBA 39.4 ± 4.1 1523 ± 36 1075 ± 44 1115 ± 31
Cisplatin 3.3 ± 1.0 11.1 ± 1.7 9.1 ± 2.1 1.7 ± 0.3
a Cells (3–5 × 104 mL−1) were treated for 72 h with increasing concentrations of the
tested compounds. The cytotoxicity was assessed by the MTT test. IC50 values were cal-
culated by a four parameter logistic model (P < 0.05). S.D. = standard deviation.
A.R.Z. Almotairy et al. Journal of Inorganic Biochemistry 177 (2017) 1–7
5
3.3. Platinum cellular accumulation
In an attempt to correlate the cytotoxic activity with cellular ac-
cumulation, the platinum content was evaluated in A431 cells treated
for 24 h with 3.125 and 6.25 μM solutions of the Pt(IV)-complexes. The
intracellular platinum amount was quantified by means of GF-AAS
analysis and the results, expressed as pg metal per 106 cells, are shown
in Fig. 3. Although to a different extent, all complexes accumulated
proportionally to drug concentration into A431 cancer cells. The cel-
lular accumulation of 3 was greater compared to that of the other
derivatives in the series and was comparable to that of cisplatin at both
tested concentrations. These results allow us to correlate the cytotoxic
activity with the ability of the Pt(IV) complexes to enter and accumu-
late into cancer cells. Interestingly, there is no correlation between li-
pophilicity and cellular internalization. Although this is somewhat
unexpected, since, unlike Pt(II) complexes, Pt(IV) complexes are be-
lieved to enter cells solely by passive diffusion, a similar lack of cor-
relation between logP values and cellular Pt accumulation has been
reported for other Pt(IV) systems [14,38,58,59].
3.4. HDAC inhibition
As the newly synthesized complexes described here were designed
to release the PBA moiety after reduction once inside the cells, we
measured the ability of these prodrugs to inhibit HDAC activity in cells.
A431 cells were incubated for 24 h with cytotoxic concentrations of the
tested compounds (5 μM) and their HDAC activity was determined. The
trend of HDAC inhibition resembles that obtained in the cytotoxicity
studies. As expected, cisplatin and carboplatin were not effective in
modifying HDAC activity (Fig. 4). Among all, compound 3 was the most
effective in hampering HDAC activity, being able to decrease the cel-
lular basal activity by roughly 18%.
3.5. Induction of apoptosis
To gain more insight into the mode of action of the newly synthe-
sized Pt(IV) complexes, we evaluated the capacity of the most effective
derivative 3 to induce apoptosis in human cervical cancer cells. In
particular, apoptotic cell death induction was confirmed through a
Hoechst 33342 staining assay. Fig. 5 shows Hoechst 33342 stained
A431 cells after 48 h treatment with IC50 concentrations of 3 or car-
boplatin. For both, compound 3 and carboplatin, treated cells as com-
pared with untreated cells, displayed chromatin condensation and
fragmentation as well as pyknotic nuclei, typical features of apoptosis.
4. Conclusions
A new series of Pt(IV) complexes based on the carboplatin scaffold
and the HDAC inhibitor PBA as an axial ligand has been synthesized,
characterized and tested on a panel of four different cancer cell lines.
The lower cytotoxic activity with respect to the reference drug cisplatin
is not unexpected and has been previously seen in other carboplatin
derivatives since carboplatin in general requires a higher dose to show a
significant anticancer activity [40]. Platinum accumulation studies re-
vealed that complex 3 shows an intracellular accumulation comparable
with that of cisplatin and indeed it possesses the highest cytotoxic ac-
tivity and HDAC inhibition potency. Lower accumulation levels and
consequently a lower cytotoxicity was observed for the other com-
plexes. The slow reduction kinetics of the Pt(IV) prodrugs of carboplatin
should also contribute to the relatively moderate cytotoxicity. Carbo-
platin is generally better tolerated than cisplatin [60] and in vivo stu-
dies could demonstrate the benefit of the carboplatin scaffold with
Fig. 3. Cellular accumulation of 1–5 and cisplatin into A431 cervical cancer cells. A431
cells were incubated for 24 h with the complexes at 3.125 and 6.25 μM concentrations.
The intracellular platinum content was determined by GF-AAS.
Fig. 4. Effects on HDAC activity induced by 1–5, cisplatin and carboplatin in A431 cer-
vical cancer cells. A431 cells were incubated for 24 h with the complexes at 5 μM con-
centration. The HDAC activity was determined by FLUOR DE LYS® HDAC fluorometric
activity assay kit (Enzo Life Sciences).
Fig. 5. Apoptosis induction. A431 cells were treated with IC50
concentrations of 3 and carboplatin for 48 h and stained with
the fluorescent dye Hoechst 33258. Ctr = untreated control.
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respect to cisplatin which, however, is beyond the aim of this paper.
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